Analyst RecommendationAnalyst reiterates a Buy rating and a $41 12-month price target.
Survival RatesFicerafusp alfa + Keytruda demonstrated a median progression-free survival of 9.9 months and a median overall survival of 21.3 months, which is notable compared to other treatments.
Treatment EfficacyThe combination of ficerafusp alfa and Keytruda showed a 54% confirmed overall response rate and a 21% complete response rate, which is superior to other treatments in similar patient populations.